'Generic drugs are experiencing faster sales growth than many branded ones, and this trend is set to continue', says visiongain.

With over 39 major drugs due to lose their patent protection before 2010,
generic companies are prepared to gain even further market share. Visiongain
predicts that there will be sustained increases in growth through 2005-2007, but
that there will be a peak in the period 2008-2010.

Visiongain also reveals that nine of the top ten fastest growing pharmaceutical
companies are generic as a result of the increasing demand for cheaper drugs.
This high growth market is especially important as branded drug growth rates are
beginning to falter for the same forecast period.

Report author Dr Gordon Low said: "It is a constantly changing market with
companies merging to improve overall competitive position."

The study examines crucial aspects of the top ten generic companies, including
recent acquisitions and mergers as well as the latest financial results of each.
The report also covers the latest generic company strategies, the success and
failure of the Hatch-Waxman Act, European regulatory issues, and important
litigation in the sector.

ENDS
Notes for editors:
To receive your complimentary overview of this report please send an email to
Sara Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711
or visit the media section on www.visiongainintelligence.com. Please include
your full name, title of publication, contact telephone number, email, and
details of where you saw this release. Upon receipt of this information, an
overview will be emailed to you.
Background:
Visiongain is one of the fastest growing and most innovative independent media
companies in Europe today. Based in London, UK, visiongain produce a host of
business-2-business conferences, newsletters, management reports and E-Zines
focusing on the Financial markets, the Pharmaceutical, Telecoms industries and
the Defence sector.
For information on visiongain, please visit www.visiongain.com